

John W Winkelman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7982032/publications.pdf>

Version: 2024-02-01

142
papers

8,342
citations

76326

40
h-index

46799

89
g-index

147
all docs

147
docs citations

147
times ranked

6255
citing authors

#	ARTICLE	IF	CITATIONS
1	Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. Sleep Medicine, 2014, 15, 860-873.	1.6	1,123
2	Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology, 2008, 70, 35-42.	1.1	375
3	Restless legs syndrome in end-stage renal disease. American Journal of Kidney Diseases, 1996, 28, 372-378.	1.9	338
4	Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Medicine, 2006, 7, 545-552.	1.6	282
5	Schizophrenia, Obesity, and Obstructive Sleep Apnea. Journal of Clinical Psychiatry, 2001, 62, 8-11.	2.2	262
6	The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Medicine, 2013, 14, 675-684.	1.6	260
7	National Use of Prescription Medications for Insomnia: NHANES 1999-2010. Sleep, 2014, 37, 343-349.	1.1	253
8	Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom) Tj ETQq0 0.0 rgBT /Overclock 10	1.6	251
9	Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019, 51, 387-393.	21.4	250
10	Serotonergic Antidepressants are Associated with REM Sleep Without Atonia. Sleep, 2004, 27, 317-321.	1.1	244
11	Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine, 2016, 21, 1-11.	1.6	242
12	Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Medicine, 2004, 5, 9-14.	1.6	234
13	Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Medicine, 2018, 41, 27-44.	1.6	228
14	Sleep Disturbance in Bipolar Disorder: Therapeutic Implications. American Journal of Psychiatry, 2008, 165, 830-843.	7.2	217
15	Antidepressants and Periodic Leg Movements of Sleep. Biological Psychiatry, 2005, 58, 510-514.	1.3	207
16	Comparison of Pregabalin with Pramipexole for Restless Legs Syndrome. New England Journal of Medicine, 2014, 370, 621-631.	27.0	189
17	Practice guideline summary: Treatment of restless legs syndrome in adults. Neurology, 2016, 87, 2585-2593.	1.1	182
18	Reduced Brain GABA in Primary Insomnia: Preliminary Data from 4T Proton Magnetic Resonance Spectroscopy (1H-MRS). Sleep, 2008, 31, 1499-1506.	1.1	164

#	ARTICLE	IF	CITATIONS
19	Clinical and Polysomnographic Features of Sleep-Related Eating Disorder. Journal of Clinical Psychiatry, 1998, 59, 14-19.	2.2	158
20	Polysomnographic and Health-related Quality of Life Correlates of Restless Legs Syndrome in the Sleep Heart Health Study. Sleep, 2009, 32, 772-778.	1.1	141
21	Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017). Movement Disorders, 2018, 33, 1077-1091.	3.9	136
22	Reduced γ -Aminobutyric Acid in Occipital and Anterior Cingulate Cortices in Primary Insomnia: a Link to Major Depressive Disorder?. Neuropsychopharmacology, 2012, 37, 1548-1557.	5.4	128
23	Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Medicine, 2003, 4, 243-246.	1.6	124
24	Increased Rostral Anterior Cingulate Cortex Volume in Chronic Primary Insomnia. Sleep, 2013, 36, 991-998.	1.1	108
25	Rotigotine improves restless legs syndrome: A 6-month randomized, double-blind, placebo-controlled trial in the United States. Movement Disorders, 2010, 25, 1675-1683.	3.9	102
26	Lack of hippocampal volume differences in primary insomnia and good sleeper controls: An MRI volumetric study at 3Tesla. Sleep Medicine, 2010, 11, 576-582.	1.6	95
27	Are Thyroid Function Tests Necessary in Patients With Suspected Sleep Apnea?. Sleep, 1996, 19, 790-793.	1.1	82
28	Restless legs syndrome and cardiovascular disease: a research roadmap. Sleep Medicine, 2017, 31, 10-17.	1.6	70
29	Sleep-Related Eating Disorder and Night Eating Syndrome: Sleep Disorders, Eating Disorders, or Both?. Sleep, 2006, 29, 876-877.	1.1	69
30	The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic Proceedings, 2021, 96, 1921-1937.	3.0	67
31	Efficacy and Tolerability of Open-Label Topiramate in the Treatment of Sleep-Related Eating Disorder. Journal of Clinical Psychiatry, 2006, 67, 1729-1734.	2.2	67
32	Periodic Limb Movements in Sleep "Endophenotype for Restless Legs Syndrome?. New England Journal of Medicine, 2007, 357, 703-705.	27.0	65
33	Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Movement Disorders, 2011, 26, 2065-2072.	3.9	65
34	Associations of Incident Cardiovascular Events With Restless Legs Syndrome and Periodic Leg Movements of Sleep in Older Men, for the Outcomes of Sleep Disorders in Older Men Study (MROS) Tj ETQq0 0 0 rBT /Overlook 10 Tf 5	1.1	65
35	Restless Legs Syndrome in Patients With Chronic Kidney Disease. Seminars in Nephrology, 2015, 35, 347-358.	1.6	55
36	Lifestyle Factors and Risk of Restless Legs Syndrome: Prospective Cohort Study. Journal of Clinical Sleep Medicine, 2016, 12, 187-194.	2.6	51

#	ARTICLE	IF	CITATIONS
37	Association of Restless Legs Syndrome With Risk of Suicide and Self-harm. JAMA Network Open, 2019, 2, e199966.	5.9	48
38	The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. Mayo Clinic Proceedings, 2018, 93, 59-67.	3.0	47
39	Restless legs syndrome and central nervous system gamma-aminobutyric acid: preliminary associations with periodic limb movements in sleep and restless leg syndrome symptom severity. Sleep Medicine, 2014, 15, 1225-1230.	1.6	46
40	Neuroimaging Studies in Insomnia. Current Psychiatry Reports, 2013, 15, 405.	4.5	44
41	An Evidence-Based Recommendation for a New Definition of Respiratory-Related Leg Movements. Sleep, 2015, 38, 295-304.	1.1	43
42	Cognitive Behavioral Therapy Using a Mobile Application Synchronizable With Wearable Devices for Insomnia Treatment: A Pilot Study. Journal of Clinical Sleep Medicine, 2017, 13, 633-640.	2.6	42
43	Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation. CNS Drugs, 2015, 29, 351-357.	5.9	41
44	Opioid- and galanin receptor heteromers mediate the dopaminergic effects of opioids. Journal of Clinical Investigation, 2019, 129, 2730-2744.	8.2	41
45	Sensory symptoms in restless legs syndrome: the enigma of pain. Sleep Medicine, 2013, 14, 934-942.	1.6	40
46	The Role of GABA in Primary Insomnia. Sleep, 2012, 35, 741-742.	1.1	38
47	Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome. Neurology, 2016, 86, 1785-1793.	1.1	38
48	The Use of Benzodiazepine Receptor Agonists and the Risk of Hospitalization for Pneumonia. Chest, 2018, 153, 161-171.	0.8	38
49	Impact of Restless Legs Syndrome on Cardiovascular Autonomic Control. Sleep, 2016, 39, 565-571.	1.1	37
50	Association between sleeping difficulty and type 2 diabetes in women. Diabetologia, 2016, 59, 719-727.	6.3	37
51	Heart Rate Response to Respiratory Events With or Without Leg Movements. Sleep, 2006, 29, 553-556.	1.1	35
52	Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 68, 434-443.	1.9	33
53	Endorsement of European guideline for the diagnosis and treatment of insomnia by the World Sleep Society. Sleep Medicine, 2021, 81, 124-126.	1.6	33
54	Restless Legs Syndrome and Psychiatric Disorders. Sleep Medicine Clinics, 2015, 10, 351-357.	2.6	30

#	ARTICLE	IF	CITATIONS
55	Probable insomnia is associated with future total energy intake and diet quality in men. American Journal of Clinical Nutrition, 2016, 104, 462-469.	4.7	29
56	Obstructive Sleep Apnea and Severe Mental Illness: Evolution and Consequences. Current Psychiatry Reports, 2012, 14, 503-510.	4.5	28
57	Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. BMC Nephrology, 2016, 17, 16.	1.8	26
58	Current Patterns and Future Directions in the Treatment of Insomnia. Annals of Clinical Psychiatry, 2005, 17, 31-40.	0.6	25
59	Energetic and Cell Membrane Metabolic Products in Patients with Primary Insomnia: A 31-Phosphorus Magnetic Resonance Spectroscopy Study at 4 Tesla. Sleep, 2013, 36, 493-500.	1.1	25
60	Sleep-related eating disorder. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 98, 577-585.	1.8	24
61	Genetic associations of periodic limb movements of sleep in the elderly for the MrOS sleep study. Sleep Medicine, 2015, 16, 1360-1365.	1.6	24
62	1H MRS Measurement of Cortical GABA and Glutamate in Primary Insomnia and Major Depressive Disorder: Relationship to Sleep Quality and Depression Severity. Journal of Affective Disorders, 2020, 274, 624-631.	4.1	24
63	Consensus Guidelines on Rodent Models of Restless Legs Syndrome. Movement Disorders, 2021, 36, 558-569.	3.9	23
64	Prevalence of restless legs syndrome during detoxification from alcohol and opioids. Journal of Substance Abuse Treatment, 2017, 73, 35-39.	2.8	22
65	Nocturnal leg cramps: Prevalence and associations with demographics, sleep disturbance symptoms, medical conditions, and cardiometabolic risk factors. PLoS ONE, 2017, 12, e0178465.	2.5	22
66	We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. Sleep Medicine Reviews, 2021, 58, 101461.	8.5	22
67	Topiramate reduces nocturnal eating in sleep-related eating disorder. Sleep, 2020, 43, .	1.1	20
68	Clinical and Polysomnographic Characteristics of High Frequency Leg Movements. Journal of Clinical Sleep Medicine, 2010, 06, 431-438.	2.6	20
69	Parasomnias. Psychiatric Clinics of North America, 2006, 29, 969-987.	1.3	18
70	Sleep and neuropsychiatric illness. Neuropsychopharmacology, 2020, 45, 1-2.	5.4	18
71	Normal Ferritin in a Patient with Iron Deficiency and RLS. Journal of Clinical Sleep Medicine, 2013, 09, 511-513.	2.6	18
72	Health status in patients with disturbed sleep and obstructive sleep apnea. Otolaryngology - Head and Neck Surgery, 2000, 122, 542-546.	1.9	17

#	ARTICLE	IF	CITATIONS
73	Prevalence and associations of respiratory-related leg movements: the MrOS sleep study. <i>Sleep Medicine</i> , 2015, 16, 1236-1244.	1.6	17
74	Sleep EEG spectral power is correlated with subjective-objective discrepancy of sleep onset latency in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 122-127.	4.8	17
75	Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry. <i>Sleep</i> , 2021, 44, .	1.1	15
76	The Long-Term Psychiatric and Cardiovascular Morbidity and Mortality of Restless Legs Syndrome and Periodic Limb Movements of Sleep. <i>Sleep Medicine Clinics</i> , 2021, 16, 279-288.	2.6	14
77	Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study. <i>Current Medical Research and Opinion</i> , 2016, 32, 77-85.	1.9	12
78	Individual periodic limb movements with arousal are temporally associated with nonsustained ventricular tachycardia: a case-crossover analysis. <i>Sleep</i> , 2019, 42, .	1.1	12
79	Difference in spectral power density of sleep EEG between patients with simple snoring and those with obstructive sleep apnoea. <i>Scientific Reports</i> , 2020, 10, 6135.	3.3	12
80	A Better Future for Patients with Restless Legs Syndrome. <i>American Journal of Medicine</i> , 2007, 120, S28-S29.	1.5	11
81	Insomnia. <i>Neurologic Clinics</i> , 2012, 30, 1045-1066.	1.8	11
82	Drug Treatment of Restless Legs Syndrome in Older Adults. <i>Drugs and Aging</i> , 2019, 36, 939-946.	2.7	11
83	The function(s) of sleep. , 0, , 59-78.		10
84	Genetic evidence for a potential causal relationship between insomnia symptoms and suicidal behavior: a Mendelian randomization study. <i>Neuropsychopharmacology</i> , 2022, 47, 1672-1679.	5.4	10
85	Major depressive disorder and insomnia: Exploring a hypothesis of a common neurological basis using waking and sleep-derived heart rate variability. <i>Journal of Psychiatric Research</i> , 2020, 123, 89-94.	3.1	9
86	Valid measures of periodic leg movements (PLMs) during a suggested immobilization test using the PAM-RL leg activity monitors require adjusting detection parameters for noise and signal in each recording. <i>Sleep Medicine</i> , 2014, 15, 132-137.	1.6	8
87	Treating Severe Refractory and Augmented Restless Legs Syndrome. <i>Chest</i> , 2022, 162, 693-700.	0.8	8
88	Therapeutic Utility of Opioids for Restless Legs Syndrome. <i>Drugs</i> , 2017, 77, 1337-1344.	10.9	7
89	Respiratory-Related Leg Movements of Sleep Are Associated With Serotonergic Antidepressants But Not Bupropion. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 1569-1576.	2.6	7
90	High national rates of high-dose dopamine agonist prescribing for restless legs syndrome. <i>Sleep</i> , 2022, 45, .	1.1	7

#	ARTICLE	IF	CITATIONS
91	Restless legs syndrome severity in the National RLS Opioid Registry during the COVID-19 pandemic. <i>Sleep Medicine</i> , 2022, 90, 96-101.	1.6	7
92	Predictors of clinical response in a double-blind placebo controlled crossover trial of gabapentin enacarbil for restless legs syndrome. <i>Sleep Medicine</i> , 2018, 48, 1-7.	1.6	6
93	Short Sleep Duration Is Associated With Increased Serum Homocysteine: Insights From a National Survey. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 139-148.	2.6	6
94	A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women. <i>Sleep</i> , 2022, 45, .	1.1	6
95	How to Identify and Fix Sleep Problems. <i>JAMA Psychiatry</i> , 2020, 77, 99.	11.0	5
96	Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2878-2888.	3.8	5
97	Restless Legs Syndrome in X-linked adrenoleukodystrophy. <i>Sleep Medicine</i> , 2022, 91, 31-34.	1.6	5
98	Designing a Sleep Disorders Curriculum for Psychiatry Residents. <i>Harvard Review of Psychiatry</i> , 2005, 13, 54-56.	2.1	4
99	A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. <i>Sleep Medicine</i> , 2016, 24, 18-23.	1.6	4
100	Restless legs syndrome and cardiovascular disease: a research roadmap: A response. <i>Sleep Medicine</i> , 2017, 36, 181.	1.6	3
101	Sleep and Marijuana Products in 2020. <i>Current Sleep Medicine Reports</i> , 2020, 6, 208-211.	1.4	3
102	Screening for Excessive Daytime Sleepiness and Diagnosing Narcolepsy. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	3
103	Depressive disorders. , 0, , 247-265.		2
104	Sleep in anxiety disorders. , 0, , 286-297.		2
105	Obstructive Sleep Apnea as a Complication of Bipolar Disorder and Its Treatment: A Review and Approach to Management. <i>primary care companion for CNS disorders</i> , The, 2017, 19, .	0.6	2
106	Restless legs syndrome: nonpharmacologic and pharmacologic treatments. <i>Geriatrics</i> , 2007, 62, 13-6.	0.3	2
107	Neuroanatomy and neurobiology of sleep and wakefulness. , 0, , 13-35.		2
108	How effective are treatment guidelines for augmented RLS?. <i>Sleep</i> , 2022, 45, .	1.1	2

#	ARTICLE	IF	CITATIONS
109	0670 Sleep-Related Event Physiologic Timing for Triggering Nonsustained Ventricular Tachycardia: A Case-crossover Analysis. <i>Sleep</i> , 2019, 42, A267-A268.	1.1	1
110	Reply to: Safety of dopamine agonists for treating restless legs syndrome. <i>Movement Disorders</i> , 2019, 34, 150-151.	3.9	1
111	Taking a sleep history. , 0, , 95-110.		1
112	Circadian rhythm disorders. , 0, , 186-202.		1
113	Principles of insomnia. , 0, , 203-215.		1
114	Treatment of insomnia: pharmacotherapy. , 0, , 216-232.		1
115	Sleep in developmental disorders. , 0, , 371-386.		1
116	Sleep in attention-deficit/hyperactivity disorder (ADHD). , 0, , 343-357.		1
117	Association between subjectiveâ€œobjective discrepancy of sleeping time and health-related quality of life: a community-based polysomnographic study. <i>Psychosomatic Medicine</i> , 2022, Publish Ahead of Print, .	2.0	1
118	Sleep in substance use disorders. , 0, , 314-329.		1
119	Sleep in pediatric mood and anxiety disorders. , 0, , 358-370.		1
120	Response to Letter to the Editor: â€œFerritin deficiency may deteriorate the symptoms of Restless Legs Syndromeâ€• <i>Sleep Medicine</i> , 2016, 22, 105.	1.6	0
121	In Replyâ€œAdditional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome. <i>Mayo Clinic Proceedings</i> , 2018, 93, 955-956.	3.0	0
122	0654 Topiramate Is Efficacious In The Treatment Of Sleep-related Eating Disorder: A Randomized, Double-blind, Placebo-controlled, Parallel Group Study. <i>Sleep</i> , 2019, 42, A261-A261.	1.1	0
123	0668 The National RLS Opioid Registry: Baseline Data on the First 300 Participants. <i>Sleep</i> , 2019, 42, A266-A267.	1.1	0
124	Reply to: A note on rotigotine for restless legs syndrome after renal transplantation. <i>Movement Disorders</i> , 2019, 34, 152-153.	3.9	0
125	532 Two-Year Longitudinal Data From the National Restless Legs Syndrome Opioid Registry. <i>Sleep</i> , 2021, 44, A209-A209.	1.1	0
126	526 Characteristics of Augmented RLS Patients on Dopamine Agonists at a Tertiary Referral Center: Where Do We Go From Here?. <i>Sleep</i> , 2021, 44, A207-A207.	1.1	0

#	ARTICLE	IF	CITATIONS
127	530 Restless Legs Syndrome Prevalence and Severity Among Patients Treated with Buprenorphine and Naloxone for Opioid Use Disorder. <i>Sleep</i> , 2021, 44, A208-A209.	1.1	0
128	Antiepileptics in the Treatment of Sleep Disorders. <i>Medical Psychiatry</i> , 2008, , 349-362.	0.2	0
129	Sleep questionnaire copyright fees can benefit research: a response to Chiang and Folz. <i>Sleep</i> , 2021, 44, .	1.1	0
130	Recognizing and Treating Excessive Daytime Sleepiness in Patients With Narcolepsy. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	0
131	Sleep medicine and psychiatry: history and significance. , 0, , 1-12.		0
132	Neurophysiology and neuroimaging of human sleep. , 0, , 36-58.		0
133	Sleep-related breathing disorders. , 0, , 111-129.		0
134	Sleep-related movement disorders. , 0, , 130-145.		0
135	Hypersomnias of central origin. , 0, , 146-159.		0
136	Parasomnias. , 0, , 160-185.		0
137	Cognitive behavioral therapy for insomnia. , 0, , 233-246.		0
138	Psychotic disorders. , 0, , 298-313.		0
139	Sleep in dementias. , 0, , 330-342.		0
140	The future at the sleep–psychiatry interface. , 0, , 387-397.		0
141	0407 Early Efficacy With Once-Nightly Sodium Oxybate (ON-SXB; FT218): Post-hoc Analyses From REST-ON. <i>Sleep</i> , 2022, 45, A182-A182.	1.1	0
142	0550 Health-Economic Implications of Defined Improvements in Restless Leg Syndrome Severity: A Model-Based Exploratory Analysis based on Prior Publication Data. <i>Sleep</i> , 2022, 45, A242-A243.	1.1	0